BROOKS LABORATORIES
|
BROOKS LABORATORIES Last 5 Year Financial Ratios History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | -3.38 | -7.46 | -8.46 | -4.57 | -7.84 |
| CEPS(Rs) | -2.84 | -6.79 | -9.63 | -4.80 | -4.90 |
| DPS(Rs) | - | - | - | - | - |
| Book NAV/Share(Rs) | 33.30 | 24.99 | 29.94 | 35.42 | 32.04 |
| Tax Rate(%) | -1.79 | -0.13 | 19.09 | 19.19 | -115.44 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 1.62 | 3.86 | -41.80 | -15.63 | 0.67 |
| EBIT Margin(%) | -10.61 | -23.55 | -57.25 | -22.81 | -7.63 |
| Pre Tax Margin(%) | -11.86 | -24.62 | -60.71 | -26.21 | -11.64 |
| PAT Margin (%) | -12.07 | -24.65 | -49.12 | -21.18 | -25.08 |
| Cash Profit Margin (%) | -10.13 | -22.42 | -38.00 | -13.12 | -15.84 |
| Performance Ratios | |||||
| ROA(%) | -9.31 | -19.59 | -20.41 | -10.83 | -11.95 |
| ROE(%) | -12.18 | -28.08 | -38.46 | -23.18 | -24.48 |
| ROCE(%) | -10.03 | -24.92 | -37.83 | -18.72 | -5.33 |
| Asset Turnover(x) | 0.77 | 0.79 | 0.42 | 0.51 | 0.48 |
| Sales/Fixed Asset(x) | 3.41 | 3.45 | 0.76 | 0.66 | 0.58 |
| Working Capital/Sales(x) | 7.48 | 9.93 | -11.67 | 7.41 | -4.75 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.29 | 0.29 | 1.31 | 1.51 | 1.73 |
| Receivable days | 80.26 | 66.75 | 87.83 | 62.77 | 64.72 |
| Inventory Days | 41.59 | 48.02 | 112.11 | 102.32 | 111.53 |
| Payable days | 98.11 | 125.11 | 185.27 | 171.35 | 237.48 |
| Valuation Parameters | |||||
| PER(x) | - | - | - | - | - |
| PCE(x) | -37.94 | -13.67 | -6.44 | -14.99 | -12.55 |
| Price/Book(x) | 3.24 | 3.71 | 2.09 | 2.05 | 1.94 |
| Yield(%) | - | - | - | - | - |
| EV/Net Sales(x) | 3.90 | 3.12 | 2.52 | 2.19 | 2.37 |
| EV/Core EBITDA(x) | 55.34 | 59.41 | -6.08 | -14.85 | 145.82 |
| EV/EBIT(x) | -36.77 | -13.24 | -4.40 | -9.60 | -31.08 |
| EV/CE(x) | 3.09 | 3.51 | 2.00 | 1.03 | 1.13 |
| M Cap / Sales | 3.84 | 3.06 | 2.45 | 1.97 | 1.99 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 3.86 | 25.76 | -30.69 | 18.04 | - |
| Core EBITDA Growth(%) | 39.52 | 115.92 | -94.85 | -1,170.52 | - |
| EBIT Growth(%) | 53.19 | 48.27 | -73.97 | -252.86 | - |
| PAT Growth(%) | 49.13 | 36.90 | -60.76 | 0.33 | - |
| EPS Growth(%) | 54.67 | 11.74 | -85.05 | 41.73 | - |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.06 | 0.08 | 0.08 | 0.28 | 0.40 |
| Current Ratio(x) | 1.48 | 1.35 | 0.84 | 1.25 | 0.74 |
| Quick Ratio(x) | 1.08 | 0.93 | 0.49 | 0.69 | 0.37 |
| Interest Cover(x) | -8.52 | -22.16 | -16.58 | -6.72 | -1.90 |
| Total Debt/Mcap(x) | 0.02 | 0.02 | 0.04 | 0.14 | 0.20 |
Compare Financial Ratios of peers of BROOKS LABORATORIES
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| BROOKS LABORATORIES | ₹273.5 Cr | -4.1% | -3.6% | -40.8% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹421,131.0 Cr | -0.7% | -0.5% | -3.1% | Stock Analytics | |
| DIVIS LABORATORIES | ₹171,862.0 Cr | 2.9% | 1.8% | 11.9% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹129,254.0 Cr | 1.5% | 3.4% | 12.4% | Stock Analytics | |
| CIPLA | ₹121,198.0 Cr | 0.2% | -0.2% | 0.4% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹107,083.0 Cr | 0.9% | 4.8% | -3.2% | Stock Analytics | |
BROOKS LABORATORIES Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| BROOKS LABORATORIES | -4.1% |
-3.6% |
-40.8% |
| SENSEX | 1% |
0.3% |
6.7% |
You may also like the below Video Courses
